RIDDLE&CODE
19.1.2021 08:10:45 CET | Business Wire | Press release
RIDDLE&CODE, an innovative European provider of secure infrastructure and technology, and Securosys, a leader in cybersecurity, encryption and digital identity protection, today announced a strategic partnership. The partnership includes the provision of Securosys HSMs for RIDDLE&CODE's Token Management Platform (TPM).
The Token Management Platform is the next generation of RIDDLE&CODE's banking-grade digital asset management solution. Operating in a secure cloud infrastructure, it delivers scalable and flexible custodial and tokenization services to the financial, energy and metal industries in Europe. Regulatory compliance has been achieved in collaboration with the Swiss financial industry.
Securosys HSMs add banking grade security features and relevant compliance processes to RIDDLE&CODE’s TMP platform.
“Our Token Management Platform is now fully interoperable with Securosys HSMs, delivering an unmatched combination of versatility and security to our customers in the energy, finance, material and mobility sectors. We are delighted to partner with Securosys and appreciate its European industry recognition and expertise. The successful deployment and integration of our software with Securosys hardware in the Swiss financial industry made this partnership a natural choice for us.” Alexander Koppel, CEO of RIDDLE&CODE.
Securosys Primus HSMs are a robust solution for securing crypto assets. Its enterprise-grade security is continuously being enhanced with additional features to protect new blockchain systems entering the market. The main advantage of HSMs is a strong security guarantee through tamper resistance and strict access controls for administrative operations.
"We are pleased to deliver our Primus HSM for Riddle&Code's Token Management Platform," said Robert Rogenmoser, CEO of Securosys. "Securosys' Blockchain HSM not only provides the best protection for private keys, but also delivers integrated multisig authentication and algorithms for distributed ledger technologies."
Riddle&Code
RIDDLE&CODE is the leading European Blockchain interface company that builds hardware and software stacks and brings trusted identity to objects and people in the financial markets, energy distribution, mobility and the Internet of Things.
Securosys SA
Securosys SA, based in Zurich, Switzerland, is a market leader in cyber security, encryption, and in securing digital identities. Founded in 2014, Securosys secures the Swiss financial markets on behalf of the Swiss National Bank and protects transactions worth over 100 billion Euros every day. The company supplies more than half of the Tier 1 banks worldwide with hardware security modules developed and built in Switzerland.
Securosys offers a wide range of security network appliances focused on commercial applications. These include communication encryption and key generation and management. All products are developed and manufactured in Switzerland, free from contaminating influences.
Further information can be obtained directly from Securosys SA by e-mail at info@securosys.ch , by calling +41 44 552 31 00, or from its offices in Zürich, Munich, and Hong Kong.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210118005375/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release
Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh
Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release
Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom